Analysis of surgical outcomes and risk factors after gonioscopy-assisted transluminal trabeculotomy

房角镜辅助经腔小梁切开术后手术结果及危险因素分析

阅读:1

Abstract

PURPOSE: This study aims to evaluate surgical outcomes as well as determine risk factors following gonioscopy-assisted transluminal trabeculotomy (GATT). METHODS: Retrospective observational study including 185 eyes (185 patients, mean age 66.7 ± 10.7 years) who underwent GATT procedure. Intraocular pressure (IOP), best-corrected visual acuity (BCVA), antiglaucoma medication (AGM) changes and surgical success rates (IOP reduction ≥ 30% from baseline and IOP < 18 mmHg, < 15 mmHg and < 12 mmHg, as Criterion A, B and C, respectively) were assessed. Cox regression analysis was used to identify risk factors in this study. RESULTS: Mean baseline and last visit IOP, BCVA and number of AGM were 32.8 ± 7.7 mmHg, 0.49 ± 0.58 and 3.8 ± 0.4, and, 12.5 ± 3.4 mmHg, 0.27 ± 0.49 and 1.7 ± 1.1, respectively. Changes in IOP, BCVA and number of AGM were significant at last visit compared to baseline (p < 0.05). Cumulative surgical success rates for Criteria A, B and C were, 86.4%, 84.7% and 54.7% at the end of the follow-up. Absence of postoperative IOP spike, age (> 60 years), mild glaucomatous damage and having pseudoexfoliation glaucoma (PEXG) were associated with higher complete surgical success for all success criteria. Qualified success rate was significantly higher in PEXG eyes than in non-PEXG eyes based on Criterion C (p < 0.0001). Complete success rates were significantly higher in PEXG eyes compared to non-PEXG eyes for all success criteria (p < 0.05). CONCLUSION: Postoperative IOP spikes, age ≤ 60 years and moderate-severe glaucomatous damage were associated with failure for complete surgical success after GATT. PEXG was a potential factor to be associated with higher surgical success even under lower target IOP levels compared to other forms of glaucoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。